TrialBlood advances2019

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Tsila Zuckerman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.